Fluticasone-salmeterol and budesonide-formoterol

Fluticasone-salmeterol and budesonide-formoterol

Drug monograph · NCLEX study reference
Trade names	Advair, Symbicort
Therapeutic class	Asthma and COPD controller
Pharmacologic class	Inhaled corticosteroid plus long-acting beta agonist combination
Onset / peak / duration	Controller effect over days; LABA gives 12-hour bronchodilation.
Half-life / level	Local plus systemic components; no routine level.
Routes	Inhaled
High-alert (ISMP)	No
Black box warning	None
Antidote / reversal	Supportive care.
Pregnancy / lactation	Use if needed.

Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.

Fluticasone-salmeterol and budesonide-formoterol (brand names Advair, Symbicort) — Asthma and COPD controller; Inhaled corticosteroid plus long-acting beta agonist combination.

Identification

• Therapeutic class: Asthma and COPD controller.
• Pharmacologic class: Inhaled corticosteroid plus long-acting beta agonist combination.

Pharmacology

• Mechanism of action: Combines anti-inflammatory steroid with sustained bronchodilation.
• Onset / peak / duration: Controller effect over days; LABA gives 12-hour bronchodilation.
• Half-life / therapeutic level: Local plus systemic components; no routine level.

Clinical use

• Indications: Asthma and COPD maintenance.
• Usual dose, route, frequency: Inhaled twice daily.
• Maximum dose / adjustments: Per product strength.

Safety

• Contraindications: Acute bronchospasm primary treatment.
• Black box warning: None (the combination format removed the prior LABA boxed warning).
• Interactions: Strong CYP3A4 inhibitors, beta blockers, QT-prolonging drugs.
• Pregnancy / lactation: Use if needed.
• High-alert: No.

Adverse effects

• Common side effects: Thrush, hoarseness, tremor, headache.
• Serious effects to report: Paradoxical bronchospasm, persistent thrush.
• Antidote / reversal: Supportive care.

Nursing process

• Assessment before administration: Respiratory status, oral mucosa.
• Interventions during therapy: Rinse mouth after use; keep a separate rescue inhaler.
• Monitor: Symptom control, heart rate.
• Evaluation / expected outcome: Improved control and fewer flares.

Patient teaching

• Patient teaching: Controller, not a rescue; rinse after use.
• Notify provider if: Increased rescue use, worsening symptoms.
• Administration tips: Twice daily; rinse mouth.